BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 7
• 8
• 9
• 10
• 11
• 14
• 15
• 16
• 17
• 18
• 21
• 22
• 23
• 24
• 25
• 28
• 29
• 30
• 31

• Press Releases

  Mitochondrial DNA Market to Reach USD 687.99 Million by 2034

  July 31, 2025

   · 

  1 min read
• 

  Immunology and inflammation

  AbbVie Carves Out Niche for Rinvoq With ‘Impressive’ Alopecia Areata Data

  Rinvoq’s efficacy in alopecia areata is “impressive,” according to Guggenheim analysts, who said the drug could have a competitive edge over other JAK inhibitors in the space.

  July 31, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results

  July 31, 2025

   · 

  1 min read
• Press Releases

  Stem Cell Therapy Market Size to Lead USD 54.45 Billion by 2034 Driven by Advancements in Regenerative Medicine and Personalized Treatments

  July 31, 2025

   · 

  1 min read
• Press Releases

  Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025

  July 31, 2025

   · 

  1 min read
• 

  Job Trends

  Greener Pastures? 81% of Employed Biopharma Professionals Want New Jobs, BioSpace Finds

  Employed biopharma professionals are highly likely to look for new jobs in the next 12 months, although not quite as likely as their unemployed counterparts, according to a BioSpace LinkedIn poll. Three recruitment experts discuss the findings and what’s driving job searches.

  July 31, 2025

   · 

  4 min read

   · 

  Angela Gabriel
• 

  Earnings

  Biogen’s Leqembi Push Getting Easier as CEO Eyes Early-Stage Pipeline Restock

  Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter earnings call. The partnered Alzheimer’s drug Leqembi saw sales climb 20% for the period.

  July 31, 2025

   · 

  4 min read

   · 

  Annalee Armstrong
• 

  Diabetes

  Lilly’s Mounjaro ‘Good Enough’ in Cardio Trial, Will Seek Expanded Approval

  While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical significance in reducing major events such as cardiovascular death, heart attack and stroke.

  July 31, 2025

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Layoffs

  Moderna Slashes Global Workforce by 10% as $1.5B Cost Cuts Hit Home

  The announced reduction of hundreds of staff came a day ahead of Moderna’s Q2 earnings report.

  July 31, 2025

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  Earnings

  Sanofi Confident Tariffs Will Have Limited Impact on Finances in 2025

  For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.

  July 31, 2025

   · 

  2 min read

   · 

  Nick Paul Taylor